Trametinib (Mekinist®, developed by Japan Tobacco, Inc. and GlaxoSmithKline) and bortezomib (Velcade®, developed by Millennium Pharmaceuticals, Inc.)have already been approved and clinically used for melanomas harbouring BRAF V600 mutations and refractory multiple myelomas, respectively39, 40, 41, 42, 43. Here, BRAF is linked to melanoma.